{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:28:57Z","timestamp":1791192537880,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81001058"],"award-info":[{"award-number":["81001058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172276"],"award-info":[{"award-number":["81172276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.canlet.2011.11.029","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T19:14:11Z","timestamp":1323285251000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Combinational therapy: New hope for pancreatic cancer?"],"prefix":"10.1016","volume":"317","author":[{"given":"Si","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2010","key":"10.1016\/j.canlet.2011.11.029_b0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2011.11.029_b0010","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0015","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/00365520902745039","article-title":"Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions","volume":"44","author":"Andersson","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.canlet.2011.11.029_b0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0305-7372(75)80003-X","article-title":"The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma","volume":"2","author":"Carter","year":"1975","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2011.11.029_b0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0360-3016(03)00448-6","article-title":"Chemotherapy for advanced pancreatic cancer","volume":"56","author":"Haller","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2011.11.029_b0030","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1985.03350380077025","article-title":"A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin","volume":"253","author":"Cullinan","year":"1985","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2011.11.029_b0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/oxfordjournals.annonc.a058495","article-title":"Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma","volume":"4","author":"Rougier","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdf197","article-title":"A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma","volume":"13","author":"Ducreux","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10555-008-9134-y","article-title":"Pancreatic cancer: from molecular pathogenesis to targeted therapy","volume":"27","author":"Strimpakos","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2011.11.029_b0050","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2002.20.1.160","article-title":"Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer","volume":"20","author":"Cartwright","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0060","first-page":"5388","article-title":"Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models","volume":"21","author":"Sawada","year":"2002","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0065","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","article-title":"Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group","volume":"25","author":"Herrmann","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0070","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2007.15.6240","article-title":"Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial \u2013 SAKK 44\/00-CECOG\/PAN.1.3.001","volume":"26","author":"Bernhard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0075","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1200\/JCO.2009.24.2446","article-title":"Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer","volume":"27","author":"Cunningham","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0080","first-page":"635","article-title":"Retrospective analysis of capecitabine and radiation therapy in the treatment of pancreatic cancer","volume":"4","author":"Saif","year":"2004","journal-title":"J. Appl. Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0085","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2005.04.030","article-title":"Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer","volume":"63","author":"Schneider","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2011.11.029_b0090","first-page":"2602","article-title":"Antitumor activity of 1M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats","volume":"56","author":"Shirasaka","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000086771","article-title":"An early phase II study of S-1 in patients with metastatic pancreatic cancer","volume":"68","author":"Ueno","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2011.11.029_b0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","article-title":"A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer","volume":"63","author":"Morizane","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2011.11.029_b0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/jjco\/hyq005","article-title":"S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure","volume":"40","author":"Todaka","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0110","doi-asserted-by":"crossref","unstructured":"B. Schultheis, D. Strumberg, L. Bergmann, U. Graeven, A.R. Hanauske, R. Lipp, J. Schuette, K. Saito, P. Scigalla, M.E. Scheulen, Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group), Invest. New Drugs (2011) April 12 (Epub ahead of print).","DOI":"10.1007\/s10637-011-9665-x"},{"key":"10.1016\/j.canlet.2011.11.029_b0115","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00280-009-0990-0","article-title":"Experimental study of combination therapy with S-1 against pancreatic cancer","volume":"64","author":"Yoshizawa","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2011.11.029_b0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00280-009-1059-9","article-title":"A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer","volume":"65","author":"Oh","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2011.11.029_b0125","doi-asserted-by":"crossref","unstructured":"T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka, Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study, J. Clin. Oncol. 29 (2011) 4007 (ASCO Meeting Abstracts).","DOI":"10.1200\/jco.2011.29.15_suppl.4007"},{"key":"10.1016\/j.canlet.2011.11.029_b0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2010.01.027","article-title":"Phase II study of oral S-1 and concurrent radiotherapy in patients with unresctable locally advanced pancreatic cancer","volume":"80","author":"Sudo","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2011.11.029_b0135","doi-asserted-by":"crossref","unstructured":"H. Shinchi, K. Maemura, Y. Mataki, H. Kurahara, M. Sakoda, S. Ueno, Y. Hiraki, M. Nakajo, S. Natsugoe, S. Takao, A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer, J. Hepatobiliary Pancreat. Sci. (2011) June 7 (Epub ahead of print).","DOI":"10.1007\/s00534-011-0400-y"},{"key":"10.1016\/j.canlet.2011.11.029_b0140","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/ajhp\/52.9.931","article-title":"FDA expands access to gemcitabine for pancreatic cancer","volume":"52","year":"1995","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.canlet.2011.11.029_b0145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2011.11.029_b0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2011.11.029_b0155","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/sj.bjc.6690568","article-title":"A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)","volume":"80","author":"Cascinu","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","article-title":"Phase I\u2013II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer","volume":"17","author":"Hidalgo","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0165","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1054\/bjoc.1999.1139","article-title":"Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study","volume":"82","author":"Matano","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000012103","article-title":"A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)","volume":"58","author":"Berlin","year":"2000","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2011.11.029_b0175","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.2002.11.149","article-title":"Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297","volume":"20","author":"Berlin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0180","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell\u2019Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0185","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","article-title":"Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer","volume":"24","author":"Heinemann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0190","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.2002.20.6.1512","article-title":"Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study","volume":"20","author":"Louvet","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0195","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bjc.6602966","article-title":"Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study","volume":"94","author":"Demols","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0205","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.2005.06.050","article-title":"Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer \u2013 a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study","volume":"23","author":"Conroy","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0210","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.11.029_b0215","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/CCO.0b013e3283473610","article-title":"Metastatic pancreatic cancer: old drugs, new paradigms","volume":"23","author":"Conroy","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1470-2045(10)70237-0","article-title":"FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?","volume":"12","author":"Kim","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5306\/wjco.v2.i3.158","article-title":"Recent progress and limitations of chemotherapy for pancreatic and biliary tract cancers","volume":"2","author":"Tada","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0230","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.bjc.6605374","article-title":"A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer","volume":"101","author":"Yoo","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0959-8049(93)90175-F","article-title":"Activity of cisplatin in adenocarcinoma of the pancreas","volume":"29A","author":"Wils","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdh098","article-title":"Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients","volume":"15","author":"Ducreux","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0245","doi-asserted-by":"crossref","unstructured":"U. Pelzer, K. Kubica, J. Stieler, I. Schwaner, G. Heil, M. G\u00f6rner, M. M\u00f6lle, A. Hilbig, B. D\u00f6rken, H. Riess, H. Oettle, A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study, J. Clin. Oncol. 26 (2008) 4508 (ASCO Meeting Abstracts).","DOI":"10.1200\/jco.2008.26.15_suppl.4508"},{"key":"10.1016\/j.canlet.2011.11.029_b0250","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1200\/JCO.1997.15.6.2414","article-title":"Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study","volume":"15","author":"Whitehead","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0255","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1040-8428(01)00184-6","article-title":"Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer","volume":"43","author":"Safran","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2011.11.029_b0260","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00006676-200310000-00003","article-title":"Docetaxel and radiotherapy and pancreatic cancer","volume":"27","author":"Viret","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2011.11.029_b0265","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10147-011-0220-8","article-title":"Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study","volume":"16","author":"Maeda","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0270","first-page":"2905","article-title":"Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study","volume":"30","author":"Saif","year":"2010","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0275","doi-asserted-by":"crossref","unstructured":"D.D. Von Hoff, R. Ramanathan, M. Borad, D. Laheru, L. Smith, T. Wood, R. Korn, N. Desai, J. Iglesias, and M. Hidalgo, SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I\/II study, J. Clin. Oncol. 27 (2009) 4525 (ASCO Meeting Abstracts).","DOI":"10.1200\/jco.2009.27.15_suppl.4525"},{"key":"10.1016\/j.canlet.2011.11.029_b0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0285","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-008-0839-y","article-title":"Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer","volume":"63","author":"Yi","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2011.11.029_b0290","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdg109","article-title":"Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer","volume":"14","author":"Stathopoulos","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0295","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3727\/096504009789745610","article-title":"Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and\/or metastatic pancreatic cancer","volume":"17","author":"Neri","year":"2009","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0300","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6603301","article-title":"A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer","volume":"95","author":"Stathopoulos","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10637-009-9265-1","article-title":"Pilot study of irinotecan\/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil-refractory pancreatic cancer","volume":"28","author":"Oh","year":"2010","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.canlet.2011.11.029_b0310","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","article-title":"Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group","volume":"47","author":"Pelzer","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0315","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2010.216135","article-title":"Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)","volume":"59","author":"Dahan","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2011.11.029_b0320","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.bjc.6605256","article-title":"A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer","volume":"101","author":"Ueno","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0325","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1200\/JCO.2008.20.9007","article-title":"Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Poplin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0330","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1245\/ASO.2003.07.018","article-title":"An experimental study on the pharmacokinetics of 5-fluorouracil regional chemotherapy for pancreatic cancer","volume":"10","author":"Mitsutsuji","year":"2003","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0335","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.1984.2.5.498","article-title":"Pharmacologic rationale for regional drug delivery","volume":"2","author":"Collins","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0340","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3760\/cma.j.issn.0366-6999.2009.03.009","article-title":"Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma","volume":"122","author":"Jin","year":"2009","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.canlet.2011.11.029_b0345","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1745-6215-12-129","article-title":"Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial","volume":"12","author":"Davis","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.canlet.2011.11.029_b0350","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0748-7983(97)93720-3","article-title":"Palliative and adjuvant regional chemotherapy in pancreatic cancer","volume":"23","author":"Link","year":"1997","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0355","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1008335331516","article-title":"Intra-arterial chemotherapy for unresectable pancreatic cancer","volume":"11","author":"Cantore","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0360","first-page":"550","article-title":"Regional chemotherapy for advanced pancreatic carcinoma","volume":"50","author":"Bayar","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.canlet.2011.11.029_b0365","first-page":"782","article-title":"Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma","volume":"11","author":"Barletta","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2011.11.029_b0370","first-page":"667","article-title":"Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome","volume":"27","author":"Pohlen","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0375","first-page":"419","article-title":"Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy","volume":"3","author":"Faller","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.canlet.2011.11.029_b0380","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0385","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/CAD.0b013e3282fc9d11","article-title":"New directions in the management of advanced pancreatic cancer: a review","volume":"19","author":"Rocha-Lima","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canlet.2011.11.029_b0390","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/CAD.0b013e3282f23287","article-title":"Cetuximab, its clinical use and future perspectives","volume":"19","author":"Rivera","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.canlet.2011.11.029_b0395","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.surg.2004.07.015","article-title":"VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer","volume":"137","author":"Hotz","year":"2005","journal-title":"Surgery"},{"key":"10.1016\/j.canlet.2011.11.029_b0400","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbrc.2003.08.073","article-title":"Expression profiles of pancreatic cancer cell lines infected with antisense K-ras-expressing adenoviral vector","volume":"309","author":"Ohnami","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2011.11.029_b0405","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/sj.bjc.6603058","article-title":"Gastrazole (JB95008), a novel CCK2\/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials","volume":"94","author":"Chau","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0410","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2002.11.151","article-title":"Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer","volume":"20","author":"Brett","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0415","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1158\/1078-0432.CCR-07-0869","article-title":"Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers","volume":"13","author":"Hassan","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0420","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0425","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-06-0952","article-title":"Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy","volume":"12","author":"Biswas","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0430","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/mt.2009.228","article-title":"Advanced phase I\/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer","volume":"18","author":"Chawla","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2011.11.029_b0435","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1158\/0008-5472.CAN-07-0674","article-title":"Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses","volume":"67","author":"Varghese","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"Vaha-Koskela","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2011.11.029_b0445","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0450","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/gt.2009.1","article-title":"Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob","volume":"16","author":"Nishimoto","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2011.11.029_b0455","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2011.11.029_b0460","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-09-1145","article-title":"A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo","volume":"9","author":"Harikumar","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2011.11.029_b0465","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/0008-5472.CAN-08-3060","article-title":"TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0470","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-09-0557","article-title":"Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts","volume":"15","author":"Li","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0475","doi-asserted-by":"crossref","first-page":"18636","DOI":"10.1073\/pnas.0709307104","article-title":"Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression","volume":"104","author":"Li","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2011.11.029_b0480","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4161\/cbt.8.7.7790","article-title":"RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles","volume":"8","author":"Luo","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2011.11.029_b0485","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-8-121","article-title":"Proteomic analysis of differential proteins in pancreatic carcinomas: effects of MBD1 knock-down by stable RNA interference","volume":"8","author":"Liu","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2011.11.029_b0490","doi-asserted-by":"crossref","unstructured":"Z. Zhang, J. Wang, B. Shen, C. Peng, M. Zheng, The ABCC4 gene is a promising target for pancreatic cancer therapy, Gene (2011) October 2 (Epub ahead of print).","DOI":"10.1016\/j.gene.2011.09.029"},{"key":"10.1016\/j.canlet.2011.11.029_b0495","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1158\/1078-0432.CCR-06-0045","article-title":"Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus","volume":"12","author":"Fu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0500","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.cgt.7700830","article-title":"The potential of oncolytic virus therapy for pancreatic cancer","volume":"12","author":"Kasuya","year":"2005","journal-title":"Cancer Gene Ther."},{"issue":"suppl. 1","key":"10.1016\/j.canlet.2011.11.029_b0505","first-page":"223","article-title":"Therapeutics with replication \u2013 selective virus (RSV) for pancreatic cancer","volume":"64","author":"Motoi","year":"2006","journal-title":"Nihon. Rinsho."},{"key":"10.1016\/j.canlet.2011.11.029_b0510","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/cgt.2010.65","article-title":"A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer","volume":"18","author":"Nakao","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2011.11.029_b0515","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2011.03.011","article-title":"Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy","volume":"307","author":"Zhou","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2011.11.029_b0520","doi-asserted-by":"crossref","unstructured":"W. Yao, X. Yu, Z. Fang, P. Yin, C. Zhao, N. Li, L. Wang, Z. Li, X. Zha, Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin beta1-actin complex in breast cancer cells, J. Cell. Mol. Med. (2011) June 21 (Epub ahead of print).","DOI":"10.1111\/j.1582-4934.2011.01369.x"},{"key":"10.1016\/j.canlet.2011.11.029_b0525","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1074\/mcp.M500178-MCP200","article-title":"Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach","volume":"5","author":"Gronborg","year":"2006","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.canlet.2011.11.029_b0530","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1517\/14728222.2010.487066","article-title":"PAR-4 as a possible new target for pancreatic cancer therapy","volume":"14","author":"Azmi","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2011.11.029_b0535","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-06-3281","article-title":"Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers","volume":"67","author":"Feldmann","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0540","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2011.11.029_b0545","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.297.17.1901","article-title":"MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis","volume":"297","author":"Bloomston","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2011.11.029_b0550","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","article-title":"MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells","volume":"4","author":"Ji","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2011.11.029_b0555","first-page":"435","article-title":"Synthetic microRNA targeting glioma-associated antigen-1 protein","volume":"487","author":"Tsuda","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2011.11.029_b0560","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0b013e3181ba82e1","article-title":"Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma","volume":"38","author":"Park","year":"2009","journal-title":"Pancreas"},{"key":"10.1016\/j.canlet.2011.11.029_b0565","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.08.065","article-title":"Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer","volume":"137","author":"Weiss","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2011.11.029_b0570","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/35023008","article-title":"Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine","volume":"406","author":"Taipale","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.11.029_b0575","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/j.bmc.2008.01.012","article-title":"Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer","volume":"16","author":"Kumar","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.canlet.2011.11.029_b0580","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1541-7786.MCR-04-0206","article-title":"Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy","volume":"3","author":"Fleming","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0585","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1078-0432.CCR-05-1571","article-title":"Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer","volume":"12","author":"Siu","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2011.11.029_b0590","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0595","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2011.11.029_b0600","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-540-71279-4_17","article-title":"NF-kappaB as a molecular target in the therapy of pancreatic carcinoma","volume":"177","author":"Sebens","year":"2008","journal-title":"Recent Results Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511007300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511007300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:33:07Z","timestamp":1759591987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511007300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0304383511007300"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.11.029","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinational therapy: New hope for pancreatic cancer?","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2011.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2011 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}